Could a simple steroid course save lives in severe respiratory infections?

NCT ID NCT07199192

Not yet recruiting Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a 7-day course of corticosteroids (like prednisolone) to hospitalized adults with severe respiratory infections and low oxygen levels can reduce deaths and the need for breathing machines. About 3,000 participants will be randomly assigned to receive the steroid or standard care without it. The goal is to see if this common anti-inflammatory drug improves survival and recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: corticosteroid (prednisolone 40 mg daily)
What this could lead to: If it works, this could confirm a standard steroid treatment to lower death risk and shorten hospital stays for severe respiratory infections.
What could go wrong: This is a large Phase 4 trial, but steroids can weaken immune response and may not help—or could even harm—some patients. Results may vary by infection type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypoxia severe acute respiratory syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOXEMIA SEVERE ACUTE RESPIRATORY SYNDROME

Contacts and locations

Locations

University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.